Trial Profile
Phase II, Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Selumetinib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 17 May 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results assessing Selumetinib plus docetaxel as 2nd line therapy in gastric cancer patients (n=27) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.